Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Corticosteroid Use in ARDS after Influenza A in Patients with Multiple Myeloma

Contraindications for Corticosteroid Use

  • The Infectious Diseases Society of America (IDSA) recommends against the use of adjunctive corticosteroid therapy for adults or children with suspected or confirmed influenza, influenza-associated pneumonia, respiratory failure, or ARDS, unless there is another clinical indication 1

Patient Characteristics to Consider

  • Patients with multiple myeloma have underlying immune suppression due to their disease and treatment 2
  • Patients with multiple myeloma are at higher risk for respiratory infections, including influenza, influenza A, and respiratory syncytial virus (RSV) 3

Exceptions for Corticosteroid Use

  • In patients with early ARDS (within 14 days of onset) not related to influenza, methylprednisolone at a dose of 1 mg/kg/day may be considered 4, 5
  • If patients have signs of critical illness-related corticosteroid insufficiency (CIRCI), hydrocortisone at a dose of <400 mg/day for ≥3 days may be considered 7

Alternative and Supportive Treatments

  • Early antiviral treatment with neuraminidase inhibitors (NAIs) is recommended for patients with influenza A 1
  • Empiric investigation and treatment of bacterial co-infections is recommended for patients with severe initial presentation (extensive pneumonia, respiratory failure, hypotension, and fever) 1

Special Considerations for Multiple Myeloma Patients

  • Annual influenza vaccination is recommended for all multiple myeloma patients, their family members, and caregivers 2
  • Vaccination should be administered before starting multiple myeloma treatment and before the start of each new influenza season 2
  • Close monitoring for signs of infection is necessary, as multiple myeloma patients are at high risk for developing opportunistic infections 2, 3